Global Coronary Artery Disease Therapeutics Market 2017-2021: Analysis By Drug Class – Research and Markets

DUBLIN--(BUSINESS WIRE)-- The "Global Coronary Artery Disease Therapeutics Market 2017-2021" report has been added to Research and Markets' offering.

The global coronary artery disease therapeutics market is expected to grow at a CAGR of 5.17% during the period 2017-2021.

The report, Global Coronary Artery Disease Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

According to the report, one of the major drivers for this market is the growing geriatric population. Globally, the geriatric population continues to grow at a faster pace mainly due to increasing life expectancy and better medical facilities. The US Census Bureau reported that in 2015, the population aged 65 years and above was 617 million, and it is expected to rise to 1,566 million by 2050.

The speed of aging and the size of the older population is remarkable in Asia. This is mainly due to the presence of a huge population in the region. However, government policies such as one child policy of China has reduced the addition of young population for a long period. Also, high investment in the healthcare sector has led to better medical facilities, thereby resulting in longer life expectancy. On the other hand, Africa is the region with the highest proportion of the young population and is expected to remain so by 2050.

Key vendors

• AstraZeneca
• Gilead
• Novartis
• Pfizer

Other prominent vendors

• Bayer,
• Bristol-Myers Squibb,
• GlaxoSmithKline,
• Merck,
• Mylan,
• Teva Pharmaceutical Industries

Key Topics Covered:

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Research Methodology

Part 04: Introduction

Part 05: Market Landscape

Part 06: Pipeline Landscape

Part 07: Market Segmentation By Drug Class

Part 08: Regional Landscape

Part 09: Decision Framework

Part 10: Drivers And Challenges

Part 11: Market Trends

Part 12: Vendor Landscape

Part 13: Vendor Analysis

Part 14: Key Vendors

For more information about this report visit https://www.researchandmarkets.com/research/4x7q4h/global_coronary

View source version on businesswire.com: http://www.businesswire.com/news/home/20171106005624/en/

Research and Markets

Laura Wood, Senior Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics: Cardiovascular Drugs

Source: Research and Markets